MIRA
INFORM REPORT
|
Report Date : |
12.09.2012 |
IDENTIFICATION DETAILS
|
Name : |
BIODEAL LABORATORIES PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
Shed No. 508, GIDC 2, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2011 |
|
|
|
|
Date of
Incorporation : |
21.02.1989 |
|
|
|
|
Com. Reg. No.: |
04-011921 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.5.100 Millions |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24231GJ1989PTC011921 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
RKTB00772C |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAACB8943 |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Manufacturer of Pharmaceutical Formulations. |
|
|
|
|
No. of Employees
: |
150 (Approximately) (In Office + In Factory) |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba (45) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 90000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Usually correct |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject company has been taken over by Sava Medica Limited in October
20, 2010 It is an established company having satisfactory track. Trade
relations are reported as fair. Business is active. Payments are reported to
be usually correct and as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
India |
A1 |
A1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INDIAN ECONOMIC OVERVIEW
India is developing into an open-market economy, yet traces of
its past autarkic policies remain. Economic liberalization, including
industrial deregulation, privatization of state-owned enterprises, and reduced
controls on foreign trade and investment, began in the early 1990s and has
served to accelerate the country's growth, which has averaged more than 7% per
year since 1997. India's diverse economy encompasses traditional village
farming, modern agriculture, handicrafts, a wide range of modern industries,
and a multitude of services. Slightly more than half of the work force is in
agriculture, but services are the major source of economic growth, accounting
for more than half of India's output, with only one-third of its labor force.
India has capitalized on its large educated English-speaking population to become
a major exporter of information technology services and software workers. In
2010, the Indian economy rebounded robustly from the global financial crisis -
in large part because of strong domestic demand - and growth exceeded 8%
year-on-year in real terms. However, India's economic growth in 2011 slowed
because of persistently high inflation and interest rates and little progress
on economic reforms. High international crude prices have exacerbated the
government's fuel subsidy expenditures contributing to a higher fiscal deficit,
and a worsening current account deficit. Little economic reform took place in
2011 largely due to corruption scandals that have slowed legislative work.
India's medium-term growth outlook is positive due to a young population and
corresponding low dependency ratio, healthy savings and investment rates, and
increasing integration into the global economy. India has many long-term
challenges that it has not yet fully addressed, including widespread poverty,
inadequate physical and social infrastructure, limited non-agricultural
employment opportunities, scarce access to quality basic and higher education,
and accommodating rural-to-urban migration.
|
Source
: CIA |
RBI DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available RBI Defaulters’ list.
EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS
Subject’s name is not enlisted as a defaulter
in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of
31-03-2012.
INFORMATION PARTED BY
|
Name : |
Ms. Leena Kothari |
|
Designation : |
AGM Finance |
|
Contact No.: |
91-20-30516100 |
|
Date : |
12.09.2012 |
LOCATIONS
|
Registered Office / Factory : |
Shed No. 508, GIDC 2, Wadhwan City, District Surendranagar - 363035,
Gujarat, India |
|
Tel. No.: |
91-2752-243730/31/32 |
|
Fax No.: |
91-2752-243733 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
15690 Sq. Mt. |
|
Location : |
Owned |
DIRECTORS
As on 30.09.2011
|
Name : |
Mr. Shailesh Ramanlal Shah |
|
Designation : |
Additional Director |
|
Address : |
F/303, 10 Kastur Kunj, CTS 2745 to 2755, Shivaji Nagar, Pune – 411013,
Maharashtra, India |
|
Date of Appointment : |
03.06.2011 |
|
DIN No.: |
00181435 |
Other Directorship:
|
S.No. |
CIN/LLPIN |
Name
of the Company/ LLP |
Current
designation of the Director/ Designated Partner |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company/
LLP Status |
Defaulting
status |
|
1 |
U74999MH1995PTC089285 |
SHREEMANT
MARKETING PRIVATE LIMITED |
Director |
07/06/1995 |
07/06/1995 |
- |
Active |
NO |
|
2 |
U72900PN2009PTC134688 |
SAVA
PRIVATE LIMITED |
Director |
17/09/2009 |
17/09/2009 |
- |
Active |
NO |
|
3 |
U51397PN2004PTC019876 |
ANAGHA
PHARMA PRIVATE LIMITED |
Director |
21/12/2009 |
21/12/2009 |
- |
Active |
NO |
|
4 |
U74999PN2010PLC135514 |
SAVA
MEDICA LIMITED |
Director |
10/02/2010 |
10/02/2010 |
- |
Active |
NO |
|
5 |
U24231GJ1989PTC011921 |
BIODEAL
LABORATORIES PRIVATE LIMITED |
Director |
30/09/2011 |
03/06/2011 |
- |
Active |
NO |
|
6 |
U74900PN2011PLC141236 |
SAVA
BIOPHARM LIMITED |
Director |
02/11/2011 |
02/11/2011 |
- |
Active |
NO |
|
7 |
U51909KA1995PTC017430 |
DHANVANTARI
BOTANICALS PRIVATE LIMITED |
Additional
director |
23/11/2011 |
23/11/2011 |
14/04/2012 |
Active |
NO |
|
8 |
U72900PN2012PTC144479 |
FIRSTPAGE
WEB TECHNOLOGIES PRIVATE LIMITED |
Director |
23/08/2012 |
23/08/2012 |
- |
Active |
NO |
|
Name : |
Mr. Vinod Ramchandra Jadhav |
|
Designation : |
Managing Director |
|
Address : |
Plot No.7, Windsor Estate, S. No.17/2B, near Bishop School, Vadgaon
Sjheri, Pune – 411014, Maharashtra, India
|
|
Date of Appointment : |
25.10.2010 |
|
DIN No.: |
00022790 |
Other Directorship:
|
S.No. |
CIN/LLPIN |
Name
of the Company/ LLP |
Current
designation of the Director/ Designated Partner |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company/
LLP Status |
Defaulting
status |
|
1 |
U51397PN2004PTC019876 |
ANAGHA
PHARMA PRIVATE LIMITED |
Director |
25/10/2004 |
25/10/2004 |
- |
Active |
NO |
|
2 |
U72900PN2009PTC134688 |
SAVA
PRIVATE LIMITED |
Director |
17/09/2009 |
17/09/2009 |
- |
Active |
NO |
|
3 |
U74999PN2010PLC135514 |
SAVA
MEDICA LIMITED |
Managing
director |
03/06/2011 |
10/02/2010 |
- |
Active |
NO |
|
4 |
U24231GJ1989PTC011921 |
BIODEAL
LABORATORIES PRIVATE LIMITED |
Managing
director |
25/10/2010 |
25/10/2010 |
- |
Active |
NO |
|
5 |
U85110KA2000PTC027824 |
GANGAGEN
BIOTECHNOLOGIES PRIVATE LIMITED |
Additional
director |
11/10/2011 |
11/10/2011 |
- |
Active |
NO |
|
6 |
U74900PN2011PLC141236 |
SAVA
BIOPHARM LIMITED |
Director |
02/11/2011 |
02/11/2011 |
- |
Active |
NO |
|
7 |
U72900PN2012PTC144479 |
FIRSTPAGE
WEB TECHNOLOGIES PRIVATE LIMITED |
Director |
23/08/2012 |
23/08/2012 |
- |
Active |
NO |
|
Name : |
Mrs. Suvarna Vinod Jadhav |
|
Designation : |
Additional Director |
|
Address : |
Plot No.7, Windsor Estate, S. No.17/2B, near Bishop School, Vadgaon
Sjheri, Pune – 411014, Maharashtra, India
|
|
Date of Appointment : |
25.10.2010 |
|
DIN No.: |
00022798 |
Other Directorship:
|
S.No. |
CIN/LLPIN |
Name
of the Company/ LLP |
Current
designation of the Director/ Designated Partner |
Date
of appointment at current designation |
Original
date of appointment |
Date
of cessation |
Company/
LLP Status |
Defaulting
status |
|
1 |
U51397PN2004PTC019876 |
ANAGHA
PHARMA PRIVATE LIMITED |
Director |
25/10/2004 |
25/10/2004 |
- |
Active |
NO |
|
2 |
U72900PN2009PTC134688 |
SAVA
PRIVATE LIMITED |
Director |
17/09/2009 |
17/09/2009 |
- |
Active |
NO |
|
3 |
U74999PN2010PLC135514 |
SAVA
MEDICA LIMITED |
Director |
10/02/2010 |
10/02/2010 |
- |
Active |
NO |
|
4 |
U24231GJ1989PTC011921 |
BIODEAL
LABORATORIES PRIVATE LIMITED |
Director |
30/09/2011 |
25/10/2010 |
- |
Active |
NO |
|
5 |
U74900PN2011PLC141236 |
SAVA
BIOPHARM LIMITED |
Director |
02/11/2011 |
02/11/2011 |
- |
Active |
NO |
|
6 |
U72900PN2012PTC144479 |
FIRSTPAGE
WEB TECHNOLOGIES PRIVATE LIMITED |
Director |
23/08/2012 |
23/08/2012 |
- |
Active |
NO |
KEY EXECUTIVES
|
Name : |
Ms. Leena Kothari |
|
Designation : |
AGM Finance |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 30.09.2011
|
Names of Shareholders |
No. of Shares |
|
|
|
Equity
Shares |
Preference
Shares |
|
Thobhanbhai K Patel |
2130 |
- |
|
Dr. Jamnadas K Patel |
1500 |
- |
|
Girdharilal M Nadpara |
1800 |
45000 |
|
Pravinbhai M Nadpara |
3600 |
- |
|
Ushaben P Nadpara |
2400 |
45000 |
|
Dr. Jamnadas K Patel (HUF) |
1500 |
- |
|
Dr. Vallabhbhai R Vaishnav |
1500 |
- |
|
Labhuben J Patel |
1500 |
- |
|
Madhuben B Patel |
3000 |
37500 |
|
Arunbhai J Patel |
2700 |
42750 |
|
Sushilaben R Patel |
8100 |
77250 |
|
Monaben R Patel |
900 |
- |
|
Tobhabhai K Patel HUF |
870 |
- |
|
Gitaben T Patel |
3000 |
45000 |
|
Kinaben S Patel |
1500 |
- |
|
Devang T Patel |
1500 |
30000 |
|
Amrutlal M Nadpara |
1200 |
- |
|
Chandrikaben A Nadpara |
1200 |
44250 |
|
Pramit A Nadpara |
900 |
- |
|
Rishit A Nadpara |
600 |
- |
|
Dr. Parshottam P Nadpara (HUF) |
2400 |
- |
|
Dr. Parshottam P Nadpara |
1200 |
- |
|
Bhavtosh P Nadpara |
1200 |
- |
|
Hetal P Nadpara |
1200 |
- |
|
Shardaben T Nadpara |
1200 |
- |
|
Jayeshbhai T Nadpara |
1200 |
- |
|
Vijaybhai T Nadpara |
1200 |
20250 |
|
Minaben G Nadpara |
600 |
- |
|
Pooja G Nadpara |
600 |
- |
|
Jeet G Nadpara |
900 |
- |
|
Dr. Vallabhbhai Vaishnav (HUF) |
900 |
- |
|
Pushaben V Vaishnav |
1800 |
- |
|
Sidharth V Vaishnav |
1200 |
40500 |
|
Jaykumar B Patel |
2700 |
- |
|
Thobhanbhai M Nadpara |
300 |
22500 |
|
Total |
60000 |
450000 |
As on 30.09.2011
Equity Share Break up (Percentage of Total Equity)
|
Category |
Percentage |
|
Directors or relatives of Directors |
100.00 |
|
Total |
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer of Pharmaceutical Formulations. |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit (30 Days and 60 Days) |
|
|
|
|
Purchasing : |
Cash and Credit (30 Days and 60 Days) |
GENERAL INFORMATION
|
Customers : |
Wholesalers, Retailers and End users |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
No. of Employees : |
150 (Approximately) (In Office + In Factory) |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Bankers : |
Axis Bank, Trishul 3rd Floor, Opposite Samartheshwar
Temple, Law Garden Ellisbridge, Ahmedabad – 380006, Gujarat, India Kotak Mahindra Bank Limited, Pune, Maharashtra, India |
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Sachin Gogave and Company Chartered Accountants |
|
Address : |
S. No. 43, Nav Maharashtra House, Opposite Shaniwar Wada, Shaniwar
Peth, Pune – 411030, Maharashtra, India |
|
PAN No.: |
AGGPG3877M |
CAPITAL STRUCTURE
As on 30.09.2011
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
660000 |
Equity Shares |
Rs.10/- each |
Rs.6.600 Millions |
|
2450000 |
9% non Cumulative Redeemable preference Shares |
Rs.10/- each |
Rs.24.500 Millions |
|
|
Total |
|
Rs.31.100
Millions |
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
|
|
|
|
|
60000 |
Equity Shares |
Rs.10/- each |
Rs.0.600
Million |
|
450000 |
9% non Cumulative Redeemable preference Shares |
Rs.10/- each |
Rs.4.500
Millions |
|
|
Total |
|
Rs.5.100 Millions |
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
5.100 |
34.000 |
34.000 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
17.411 |
183.544 |
203.734 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
22.511 |
217.544 |
237.734 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
(3.369) |
33.352 |
27.826 |
|
|
2] Unsecured Loans |
152.515 |
131.344 |
150.930 |
|
|
TOTAL BORROWING |
149.146 |
164.696 |
178.756 |
|
|
DEFERRED TAX LIABILITIES |
7.860 |
28.448 |
29.313 |
|
|
|
|
|
|
|
|
TOTAL |
179.517 |
410.688 |
445.803 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
133.241 |
127.741 |
232.270 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.202 |
0.297 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
36.852
|
24.743 |
44.860 |
|
|
Sundry Debtors |
45.938
|
43.497 |
113.189 |
|
|
Cash & Bank Balances |
6.818
|
0.665 |
10.915 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
46.445
|
269.860 |
110.983 |
|
Total
Current Assets |
136.053
|
338.765 |
279.947 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
23.326 |
15.457 |
40.980 |
|
|
Other Current Liabilities |
54.851
|
30.363 |
16.423 |
|
|
Provisions |
11.600
|
10.200 |
9.308 |
|
Total
Current Liabilities |
89.777
|
56.020 |
66.711 |
|
|
Net Current Assets |
46.276
|
282.745 |
213.236 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
179.517 |
410.688 |
445.803 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
|
|
519.613 |
|
|
|
Other Income |
|
|
15.679 |
|
|
|
TOTAL |
262.018 |
270.389 |
535.292 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Office Expenses |
|
|
|
|
|
|
Administrative Expenses |
|
|
|
|
|
|
Advertising Expenses |
|
|
|
|
|
|
TOTAL |
229.889 |
250.910 |
494.927 |
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX |
32.129 |
19.479 |
40.365 |
|
|
|
|
|
|
|
|
|
Less |
TAX |
10.887 |
10.358 |
21.591 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
|
21.242 |
9.121 |
18.775 |
|
|
|
|
|
|
|
|
|
|
EARNINGS IN
FOREIGN CURRENCY |
84.741 |
107.835 |
104.990 |
|
|
|
|
|
|
|
|
|
|
IMPORTS |
|
|
|
|
|
|
|
Raw Materials |
31.707 |
30.067 |
7.707 |
|
|
|
Capital Goods |
16.232 |
0.000 |
0.000 |
|
|
TOTAL IMPORTS |
47.939 |
30.067 |
7.707 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
41.65 |
NA |
NA |
|
|
Particulars |
|
|
31.03.2012 |
|
Sales Turnover (Approximately) |
|
|
270.000 |
Expected Sales (2012-2013) : Above Rs.300.000 Millions
The above information has been parted by Ms. Leena Kothari.
KEY RATIOS
|
PARTICULARS |
|
31.03.2011 |
31.03.2010 |
31.03.2009 |
|
PAT / Total Income |
(%) |
8.11
|
3.37 |
3.51 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
NA
|
NA |
7.77 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
11.93
|
4.18 |
7.88 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
1.43
|
0.09 |
0.17 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
10.61
|
1.01 |
1.03 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.52
|
6.05 |
4.20 |
LOCAL AGENCY FURTHER INFORMATION
|
Sr. No. |
Check List by Info Agents |
Available in
Report (Yes / No) |
|
1] |
Year of Establishment |
Yes |
|
2] |
Locality of the firm |
Yes |
|
3] |
Constitutions of the firm |
Yes |
|
4] |
Premises details |
Yes |
|
5] |
Type of Business |
Yes |
|
6] |
Line of Business |
Yes |
|
7] |
Promoter's background |
Yes |
|
8] |
No. of employees |
Yes |
|
9] |
Name of person contacted |
Yes |
|
10] |
Designation of contact
person |
Yes |
|
11] |
Turnover of firm for last
three years |
Yes |
|
12] |
Profitability for last
three years |
Yes |
|
13] |
Reasons for variation
<> 20% |
-- |
|
14] |
Estimation for coming
financial year |
Yes |
|
15] |
Capital in the business |
Yes |
|
16] |
Details of sister
concerns |
No |
|
17] |
Major suppliers |
No |
|
18] |
Major customers |
No |
|
19] |
Payments terms |
Yes |
|
20] |
Export / Import details
(if applicable) |
No |
|
21] |
Market information |
-- |
|
22] |
Litigations that the firm
/ promoter involved in |
-- |
|
23] |
Banking Details |
Yes |
|
24] |
Banking facility details |
Yes |
|
25] |
Conduct of the banking
account |
-- |
|
26] |
Buyer visit details |
-- |
|
27] |
Financials, if provided |
Yes |
|
28] |
Incorporation details, if
applicable |
Yes |
|
29] |
Last accounts filed at
ROC |
Yes |
|
30] |
Major Shareholders, if
available |
Yes |
|
31] |
Date of Birth of
Proprietor/Partner/Director, if available |
No |
|
32] |
PAN of
Proprietor/Partner/Director, if available |
No |
|
33] |
Voter ID No of
Proprietor/Partner/Director, if available |
No |
|
34] |
External Agency Rating,
if available |
No |
OPERATING RESULTS:
The overall performance of the company has remained most satisfactory.
The company has achieved its budgeted targets in respect of its turnover and profitability.
The management is also very hopeful to achieve good results as per the targets
during the year.
FIXED ASSETS:
·
Land
·
Building
·
Plant and Machinery
·
Furniture and Fittings
·
Office Equipments
·
Vehicles
WEBSITE DETAILS:
OVERVIEW
Subject was established in 1982 as a contract
manufacturer for the Indian market. subject is an independent State- of- the-
art -manufacturing unit having modern and sophisticated manufacturing
facilities of international standards which include ultra-modern plant,
machineries , equipments and documents as per the technical guideline of
Rhone-Poulenc (India) Limited. Subject has been in the frontiers of Indian
pharma manufacturing sector erstwhile establishing legacy of various national
and multinational pharma company.
SAVA MEDICA LIMITED, esteemed 2003, with its
strong international distribution background and marketing credence in across
30 geographies world-over has acquired subject on the auspicious day of October
20, 2010 in consonance with its inorganic vertical integration strategy. The
SAVA group has ambitious plans of becoming a millennium growth company with its
seamless integration of marketing efforts and manufacturing assets. SAVA group
thus enhances its international legacy with its multi-faceted momentous growth
across the pharma value chain.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government official
or a family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on Corporate
Governance to identify management and governance. These factors often have been
predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.26 |
|
|
1 |
Rs.88.85 |
|
Euro |
1 |
Rs.71.13 |
INFORMATION DETAILS
|
Information Gathered
by : |
JML |
|
|
|
|
Report Prepared
by : |
BSN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
6 |
|
PAID-UP CAPITAL |
1~10 |
5 |
|
OPERATING SCALE |
1~10 |
5 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
5 |
|
--PROFITABILIRY |
1~10 |
5 |
|
--LIQUIDITY |
1~10 |
5 |
|
--LEVERAGE |
1~10 |
5 |
|
--RESERVES |
1~10 |
5 |
|
--CREDIT LINES |
1~10 |
4 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
45 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.